Rubius Therapeutics Stock Forecast, Price & News

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RUBY shares have decreased by 2.0% and is now trading at $6.42.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Rubius Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Rubius Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rubius Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Rubius Therapeutics.

Rubius Therapeutics, Inc. (NASDAQ:RUBY) posted its earnings results on Monday, November, 9th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.01.
View Rubius Therapeutics' earnings history.

5 equities research analysts have issued 12-month target prices for Rubius Therapeutics' shares. Their forecasts range from $4.00 to $28.00. On average, they expect Rubius Therapeutics' share price to reach $11.40 in the next year. This suggests a possible upside of 77.6% from the stock's current price.
View analysts' price targets for Rubius Therapeutics.

Some companies that are related to Rubius Therapeutics include Sorrento Therapeutics (SRNE), Kymera Therapeutics (KYMR), NanoString Technologies (NSTG), Editas Medicine (EDIT), Atara Biotherapeutics (ATRA), Vaxcyte (PCVX), Forma Therapeutics (FMTX), Mesoblast (MESO), Bavarian Nordic A/S (BVNRY), Scholar Rock (SRRK), C4 Therapeutics (CCCC), Cortexyme (CRTX), Translate Bio (TBIO), Sangamo Therapeutics (SGMO) and REGENXBIO (RGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Marinus Pharmaceuticals (MRNS), Xeris Pharmaceuticals (XERS), Fulcrum Therapeutics (FULC), Recro Pharma (REPH), TG Therapeutics (TGTX), Tilray (TLRY), Viking Therapeutics (VKTX), ADMA Biologics (ADMA) and Adverum Biotechnologies (ADVM).

(RUBY) raised $200 million in an initial public offering on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Rubius Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.07%), JPMorgan Chase & Co. (2.85%), State Street Corp (0.84%), Charles Schwab Investment Management Inc. (0.29%), California Public Employees Retirement System (0.09%) and Arrowstreet Capital Limited Partnership (0.07%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Pablo J Cagnoni, Robert Langer and Torben Straight Nissen.
View institutional ownership trends for Rubius Therapeutics.

RUBY stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., SG Americas Securities LLC, UBS Asset Management Americas Inc., State Street Corp, Virtus ETF Advisers LLC, Aperio Group LLC, and Great West Life Assurance Co. Can.
View insider buying and selling activity for Rubius Therapeutics.

RUBY stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Jane Street Group LLC, DekaBank Deutsche Girozentrale, Squarepoint Ops LLC, Paloma Partners Management Co, Schonfeld Strategic Advisors LLC, Schonfeld Strategic Advisors LLC, and Public Employees Retirement System of Ohio. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, and Pablo J Cagnoni.
View insider buying and selling activity for Rubius Therapeutics.

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RUBY stock can currently be purchased for approximately $6.42.

Rubius Therapeutics has a market capitalization of $519.53 million. The company earns $-163,460,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Rubius Therapeutics employs 199 workers across the globe.

The official website for Rubius Therapeutics is www.rubiustx.com.

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]